BERLIN (Reuters), Sep 22 - A daily dose of aspirin can prevent cancer in people with a genetic disorder that increases their risk of developing the disease, scientists said on Monday.
The finding could also have important implications for the wider population, although more research is needed and unraveling the connection will take some time because the benefits of aspirin were only seen after several years.
John Burn of the Institute of Human Genetics at Newcastle University in Britain said his study might also have uncovered a simple way of controlling stem cells that make tumors grow.
"We believe that aspirin may have an effect on the survival of aberrant (faulty) stem cells in the colon," Burn said, presenting his findings at the ECCO-ESMO European cancer congress in Berlin.
Burn and colleagues tested 1,071 people with Lynch syndrome -- an inherited condition that predisposes a person to a range of cancers, particularly of the colon -- by giving some of them aspirin and some a placebo.
Follow-up tests after 10 years showed that although there was no difference in cancer rates after 29 months, a significant difference was detected after four years, with fewer people in the aspirin group developing colon cancer, Burn said.
"To date, there have been only six colon cancers in the aspirin group as opposed to 16 who took placebo," he added. "There is also a reduction in endometrial cancer."
People with Lynch syndrome have an increased risk of many cancers including stomach, colon, brain, skin, and prostate. Women carriers also have a high risk of developing endometrial and ovarian cancers.
Burn said that although people in the trial stopped taking aspirin, its effect clearly continued.
Colorectal is the second biggest cause of cancer death in the U.S. and Europe, where a total of 560,000 people develop the disease each year and 250,000 die from it.
Aspirin, originally developed by Bayer, is a cheap over-the-counter drug that in low daily doses has been found to stave off the risk of heart attacks and strokes, as well as chase away occasional aches and pains.
Other scientists have previously found it can reduce the risk of developing colon cancer and suggested it does so by blocking the enzyme cyclooxygenase-2, or COX-2, which promotes inflammation and cell division and is found in high levels in tumors.
But Burn said he thought this explanation was unlikely, and thinks that aspirin hits faulty stem cells before they mutate into precancerous cells.
"If aspirin reduced the chances of such cells surviving, this would explain our results," he said.
Despite its benefits, aspirin is also well known for causing stomach upset. In the study, 11 patients on aspirin had stomach bleeds or ulcers compared with nine on placebo.
The team plans a further study using a larger group of patients taking differing aspirin doses.
By Kate Kelland
Last Updated: 2009-09-21 10:25:13 -0400 (Reuters Health)
Related Reading
Aspirin cuts colon cancer death risk: U.S. study, August 12, 2009
Copyright © 2009 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
